Jul. 20 at 3:02 PM
The attached table lists all 164 new commercial-stage non-oncology focused bios since 1/1/2013 (1st FDA approval) noting the share price as of the close on the day after FDA approval. Obviously non-public bios are excluded
Of the 164, 48 or 29% were acquired. Of the 48, 25 were acquired at gains (versus share price at FDA approval) & 23 were acquired at a lower share price.
19 of the 164 went bankrupt or were delisted where investors lost virtually everything.
Of the 97 still independent today, only 35 trade higher where 62 trade lower.
Net net roughly 1 of 3 delivered gains where investors are down in 2 of every 3. As disappointing as it appears, oncology has fared slightly worse. Of course things could change
New commercial-stage bios that are still independent today (excl M&A) that delivered the biggest gains in share price to shareholders were were
$VCEL $CPRX $ADMA $INSM $ZEAL
We track these data points manually so of course we may have missed 1 or 2. Also, there may be splits missed
